Mehtap PEHLİVANLAR KÜÇÜK, Ahmet Oğuzhan KÜÇÜK, Gamze KILIÇ, Yılmaz BÜLBÜL, Tevfik ÖZLÜ, Ayşegül PEHLİVANLAR, Funda ÖZTUNA, Sevil AYAYDIN MÜRTEZAOĞLU, Kadir ÇOBAN, Olcay AYÇİÇEK

Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study

Backround/aim: In this study, the efficacy of an IL-6 antagonist, Tocilizumab, administered in the early period was studied in intensive care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation not receiving mechanical ventilation support. Materials and methods: Patients with COVID-19 pneumonia who have signs of hypoxia and systemic inflammation and/or who have acute bilateral infiltrates on chest radiograph and who received tocilizumab treatment were compared with the patients who received standard medical therapy. Patients who were followed up with COVID-19 pneumonia and respiratory failure between March 2020 and March 2021 were retrospectively evaluated in the study. A 400 mg – 800 mg iv dose (depending on weight) of Tocilizumab was administered. The primary endpoint was determined as intensive care unit mortality. Results: A total of 213 patients who were admitted with respiratory failure associated with COVID-19 to our third-level intensive care unit were evaluated. Of these patients, the study was conducted with 50 patients in the tocilizumab treatment group and 92 patients in the standard treatment group. During the intensive care period, 26 patients (28.3%) in the standard treatment group and 12 patients (24%) in the group receiving tocilizumab died. The adjusted hazard ratio for mortality in the tocilizumab group was 0.39 (95% confidence interval [CI], 0.186 to 0.808; p = 0.001 by log-rank test). During the intensive care period, 22 patients (24.8%) in the standart treatment group and 16 patients (32%) in the tocilizumab group were intubated. The adjusted hazard ratio for a primary outcome intubation in the tocilizumab group was 0.71 (95% confidence interval [CI], 0.355 to 1.424; p = 0.184 by log-rank test). Conclusion: Tocilizumab was administered with a low-dose steroid or following pulse steroid in intensive care patients followed up with COVID-19 pneumonia and evidence of hypoxia, and systemic inflammation was shown to reduce the intensive care all-cause mortality.

PDF

___

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA - Journal of the American Medical Association 2020; 323 (8): 709–710. doi: 10.1001/ jama.2020.1097
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - Journal of the American Medical Association 2020; 323 (13): 1239–1242. doi: 10.1001/jama.2020.2648
3. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395 (10223): 507–513. doi: 10.1016/S0140- 6736(20)30211-7
4. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124 (2): 188–195. doi: 10.1182/ blood-2014-05-552729
5. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395 (10223): 497–506. doi: 10.1016/ S0140-6736(20)30183-5
6. Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. Journal of Clinical Investigation 2020; 130 (5): 2202–2205. doi: 10.1172/ JCI137647
7. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA et al. Cytokine release syndrome. Journal for ImmunoTherapy of Cancer 2018; 6 (1): 56. doi: 10.1186/ s40425-018-0343-9
8. Chen G, Wu D, Guo W, Cao Y, Huang D et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation 2020; 130 (5): 2620–2629. doi: 10.1172/JCI137244
9. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation 2019; 25 (4): e123–127. doi: 10.1016/j. bbmt.2018.12.756
10. Fernández-Ruiz M, López-Medrano F, Pérez-Jacoiste Asín MA, Maestro de la Calle G, Bueno H et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. Journal of Medical Virology 2021; 93 (2): 831–842. doi: 10.1002/jmv.26308
11. Salama C, Han J, Yau L, Reiss WG, Kramer B et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. New England Journal of Medicine 2021; 384 (1): 20–30. doi: 10.1056/nejmoa2030340
12. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2021; 397 (10285): 1637–1645. doi: 10.1016/ S0140-6736(21)00676-0
13. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine 2020; 383 (24): 2333–2344. doi: 10.1056/nejmoa2028836
14. Biran N, Ip A, Ahn J, Go RC, Wang S et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology 2020; 2 (10): e603–612. doi: 10.1016/S2665-9913(20)30277-0
15. Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M et al. Surviving Sepsis Campaign Guidelines on the Management of Adults with Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine 2021; 49 (3): E219– 234. doi: 10.1097/CCM.0000000000004899
16. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): A European respiratory society living guideline. European Respiratory Journal 2021; 57 (4): 2100048. doi: 10.1183/13993003.00048-2021
17. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. New England Journal of Medicine 2021; 384 (16): 1503–1516. doi: 10.1056/nejmoa2028700
18. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine 2021; 181 (1): 32–40. doi: 10.1001/jamainternmed.2020.6820
19. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized with COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine 2021; 181 (1): 24–31. doi: 10.1001/jamainternmed.2020.6615
20. Ware LB. Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020; 8 (12): 1163–1165. doi: 10.1016/S2213-2600(20)30369-6
21. Escadafal C, Incardona S, Fernandez-Carballo BL, Dittrich S. The good and the bad: using C reactive protein to distinguish bacterial from non-bacterial infection among febrile patients in low-resource settings. BMJ Global Health 2020; 5 (5): e002396. doi: 10.1136/bmjgh-2020-002396